Knowthestock.com
ALXN - Alexion Pharmaceuticals Inc.
SNP 500NASDAQ

Hold

Strong Growth and Stable

68%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 18.24%
Operating Income Growth is -75.08%
Net Income Growth is -71.28%
Earnings Per Share (EPS) Growth is -71.19%
Net Margin is 10.89%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.52
Debt Ratio is 0.33
Current Debt to Net Income Ratio is 0.23
Total Debt to Total Assets Ratio is 0.14
Cash Flow is STRONG
Cash from Operations Growth is 40.2%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alexion Pharmaceuticals Inc. (ALXN) - www.alxn.com
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO -
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.